---

EVALUATION OF CLINICAL EFFICACY AND SAFETY OF OVARYL TABLET AN HERBAL FORMULATION IN POLY CYSTIC OVARIAN SYNDROME (PCOS)

---

Null

Author Details : Manish R. Pandya, Dharmesh K. Golwala, Kalpana Khandheria

Volume : 2, Issue : 2, Year : 2015

Article Page : 73-91

Suggest article by email

Get Permission

---

Abstract

Background: To evaluate the clinical efficacy and safety effect of Ovaryl tablet a marketed herbal formulation of Mercury Laboratories Ltd., in Poly cystic Ovarian Syndrome.

Methods: 58 women patients’ age range between 20 to 40 years, suffering from Poly cystic Ovarian Syndrome symptoms like hirsutism, irregular periods, ovulation, volume of ovary, weight and serum insulin levels.

Results: A significant improvement was observed in clinical symptoms like hirsutism, irregular periods and ovulation after MOT medication.Laboratory investigation showed decrease in Serum Insulin levels. A minimum decrease of 2.87% and 36.73% maximum decrease of serum insulin levels were observed on 90th day of MOT treatment. 22.06% maximum and 1.55% minimum decrease of ovary volume in Right Ovary. 24.39% maximum and 1.37% minimum decrease of ovary volume in Left Ovary was observed. Upper Abdomen USG was normal in all the 58 patients, no cyst was reported.

Conclusion: Poly cystic Ovarian Syndrome symptoms like hirsutism, irregular periods, ovulation, and volume of ovary, weight and serum insulin levels were taken care off.

Key words: Ovaryl tablet, Poly cystic ovarian syndrome, Serum insulin level and Ovary volume.

How to cite : Pandya M R, Golwala D K, Khandheria K, EVALUATION OF CLINICAL EFFICACY AND SAFETY OF OVARYL TABLET AN HERBAL FORMULATION IN POLY CYSTIC OVARIAN SYNDROME (PCOS). Indian J Obstet Gynecol Res 2015;2(2):73-91

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.